.
For all antibiotics tested, the MIC breakpoints recommended by the CLSI were used. Since CLSI did not provide MIC breakpoints for moxifloxacin against any organisms other than staphylococci (<0.5 μg/ml for susceptibility), the MIC breakpoints used for moxifloxacin against all other organisms were <1 μg/ml for susceptibility, >2 μg/ml for resistance [9] . Quality control was performed by testing American Type Culture Collection (ATCC) strains E. coli 25922 and 35218, S. aureus 29213, E. faecalis 29212 and P. aeruginosa 27853.
Moxifloxacin displayed excellent in vitro activity against staphylococci and viridans streptococci, and compared with all other quinolones, it had the lowest MIC90 against coagulase-negative staphylococci, S. aureus, S. oralis and S. mitis (Table 1 ). The better activity against viridans streptococci is particularly interesting, and might reduce the need to add a beta-lactam for the oral treatment of fever in low-risk neutropenic patients. Compared with ciprofloxacin, moxifloxacin exhibits increased, but still only relatively modest activity against enterococci.
Against E. coli, the MIC 90 of all fluoroquinolones tested was between 8 and 16 μg/ml: 9 of 44 isolates were highly resistant. These highly resistant organisms were isolated from nine patients hospitalized in six different centers. Six of the nine patients with fluoroquinolone-resistant E. coli had received quinolone prophylaxis before the occurrence of the bacteremic episode. In contrast, none of 35 patients infected with fluoroquinolone-susceptible E. coli strains had received fluoroquinolone prophylaxis (Fisher's test p<0.001). Thus, as previously described in EORTC-IDG trials, infections due to fluoroquinolone-resistant E. coli still occur in high-risk patients who receive fluoroquinolone prophylaxis, even though its use decreased from 52% in the trial performed over 1993-1994 [5] to 33% in the trial performed over 1997-2000 [6] . Regarding other gramnegative isolates, moxifloxacin is highly active against Klebsiella spp and was less active than ciprofloxacin against P. aeruginosa.
Rolston et al. [10] tested the in vitro activity of moxifloxacin against 900 strains isolated from cancer patients: two thirds of these strains were bloodstream isolates. As in the present study, moxifloxacin was the most active fluoroquinolone against coagulase-negative staphylococci, S. aureus and viridans streptococci. These researchers also reported fluoroquinolone-resistant E. coli related to previous prophylaxis and lower in vitro activity of moxifloxacin against P. aeruginosa compared with ciprofloxacin.
The susceptibility of the EORTC-IDG strains to various antibiotics commonly used in neutropenic patients has been tested. As shown for bacteria isolated from neutropenic patients in US cancer centers [11] , the highest rates of susceptibility were observed with cefepime and meropenem, which are active against 100% of viridans streptococci, E. coli and Klebsiella spp. Amikacin is active against all gram-negative bacteria including P. aeruginosa, and ceftazidime is active against the vast majority of E. coli, Klebsiella spp and P. aeruginosa.
In conclusion, this study confirms that moxifloxacin exhibits increased in vitro activity relative to older fluoroquinolones against gram-positive bacteria isolated from the blood of neutropenic patients. In areas with low fluoroquinolone resistance among Enterobacteriaceae, these findings could support the use of single-drug oral regimens in low-risk febrile neutropenic patients. This in turn might provide a potential benefit in terms of compliance, especially for outpatients. Although the moderate in vitro activity of moxifloxacin against P. aeruginosa might be a potential problem, this non-fermentative bacteria is currently isolated only infrequently from the blood of low-risk neutropenic cancer patients. Since the emergence of resistant E. coli was observed in patients receiving fluoroquinolone prophylaxis, this practice should be avoided in low-risk neutropenic patients as it might limit the use of fluoroquinolones as oral therapeutic agents. 
